Deal facts
- Buyer
- Brains Therapeutics Corp.
- Target
- Brains Bioceutical Corp.
- Deal value
- USD 750,000,000
- Announced
- 5 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- Canada
- Consideration
- shares, earn-out
Sources
Armada Acquisition Corp. III, a Cayman Islands SPAC, signed a Business Combination Agreement on October 31, 2026 with Armada Sponsor III, LLC, Brains Bioceutical Corp. and Brains Therapeutics Corp. Brains Bioceutical is a British Columbia company, and Brains Therapeutics (called PubCo in the filing), also incorporated in British Columbia, will become the listed parent. The 8-K, signed November 5, 2026, says the SPAC and Brains issued a joint press release that day announcing the agreement.
Brains Bioceutical is a pharmaceutical company combining an established EU-GMP manufacturing and regulatory platform with proprietary and partnered drug-development programs focused on cannabinoid-based therapeutics. Through its subsidiary BSPG Laboratories Limited, it operates an MHRA-inspected and registered API manufacturing facility in Kent, England. It is headquartered in Vancouver.
Brains security holders will receive newly issued PubCo shares, rollover equity awards and rollover warrants. These are attributable to a transaction value starting from a $750.0 million Enterprise Value. That figure is reduced by the estimated closing balance sheet adjustment and by Company expenses above $10.0 million, and increased by SPAC transaction expenses above $10.0 million. The result is divided by a $10.20 reference value per share. The filing also provides for 14,705,882 earnout shares, issued at closing and held in escrow. Half are released if PubCo's volume-weighted average price reaches $12.50 and the other half at $15.00, for at least 20 trading days within any 30-trading-day period between six months and three years after closing. A change of control at or above those prices also triggers release.
The mechanics run in two steps. A Cayman merger first makes the SPAC a wholly owned subsidiary of PubCo, with each SPAC Class A share exchanged for one PubCo share. On the closing date, a PubCo subsidiary then amalgamates with Brains under a British Columbia plan of arrangement, and Brains becomes a wholly owned PubCo subsidiary. Closing conditions include SPAC shareholder approval, approval of the arrangement by holders of not less than two-thirds of the Company common shares present in person or represented by proxy at the Company shareholders meeting, interim and final orders from the Supreme Court of British Columbia, an effective Form F-4 registration statement and approval of PubCo's initial listing application on Nasdaq or another agreed exchange. They also include PubCo having at least $5,000,001 of consolidated net tangible assets after the transactions, and dissent rights exercised by holders of less than 5.0% of Company shares. The parties are to seek up to $100.0 million of transaction financings. Either the SPAC or Brains may terminate if closing has not occurred by June 30, 2027.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
Brains Therapeutics Corp. firm intention to acquire Brains Bioceutical Corp.
Item 1.01 Entry into a Material Definitive Agreement. Business Combination Agreement General On October 31, 2026, Armada Acquisition Corp. III, a Cayman Islands exempted company (“ SPAC ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”) with Armada Sponsor III, LLC, a Delaware limited liability company (the “ Sponsor ”), Brains Bioceutical Corp., a company e
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Brains Therapeutics Corp.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive